HGG

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Retrieved on: 
Wednesday, September 13, 2023
City of Hope, California Institute for Regenerative Medicine, Allotransplantation, Investigational New Drug, Acquisition, Patient, CIRM, NYSE, Journal of Translational Medicine, PIPE, Research, Cancer, CGMP, Security (finance), The Lancet, FDA, III, IND, Safety, LLP, Interim, FLAG, Stem cell, Acute myeloid leukemia, Translational medicine, Form, WHO, B cell, Weil, Gotshal & Manges, Triple-negative breast cancer, Regenerative medicine, AML, City, Melanoma, HGG, LP, Supernova, Bank, Commercial property, Pharmaceutical industry, Vaccine, Hope

The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders.

Key Points: 
  • The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders.
  • Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.
  • The Company believes that the proceeds available to the Company from the transactions will be sufficient to fund its operations into 2025.
  • “We founded Calidi in 2014 with a mission to develop a new generation of targeted immunotherapies that could revolutionize the treatment of cancer,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Retrieved on: 
Wednesday, September 13, 2023
Oncology, Health, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, Northwest Biotherapeutics, City of Hope, California Institute for Regenerative Medicine, Allotransplantation, Investigational New Drug, Acquisition, Patient, CIRM, NYSE, Journal of Translational Medicine, PIPE, Research, Cancer, CGMP, Security (finance), The Lancet, FDA, III, IND, Safety, LLP, Interim, FLAG, Stem cell, Acute myeloid leukemia, Translational medicine, Form, WHO, B cell, Weil, Gotshal & Manges, Triple-negative breast cancer, Regenerative medicine, AML, City, Melanoma, HGG, LP, Supernova, Pharmaceutical industry, Vaccine, Hope

The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders.

Key Points: 
  • The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders.
  • Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.
  • The Company believes that the proceeds available to the Company from the transactions will be sufficient to fund its operations into 2025.
  • “We founded Calidi in 2014 with a mission to develop a new generation of targeted immunotherapies that could revolutionize the treatment of cancer,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.

Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, August 10, 2023
Injection, Insurance, Gene, Survival, Clinical trial, Nestin, NSCLC, SOC, Lung cancer, American Society of Gene and Cell Therapy, Pharmacist, ASCO, Development, American Society of Clinical Oncology, MD, Patient, Standard of care, Administration, HGG, Annual general meeting, Cell, Research, MOS, Break, Therapy, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Video game, Candel, Doctor of Philosophy, Fellow of the Academy of Medical Sciences, Q4

NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
  • Research and Development Expenses: Research and development expenses were $5.9 million for the second quarter of 2023 compared to $5.0 million for the second quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $3.6 million for the second quarter of 2023 compared to $3.8 million for the second quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the second quarter of 2023 and the second quarter of 2022.

Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference

Retrieved on: 
Thursday, July 27, 2023
Society, Safety, SNO, Plus Therapeutics, CNS, Central nervous system, ASCO, Convection, Pakistan Society of Neuro-Oncology, HGG, CED, LM, PSTV, Decompression (diving), Therapy, Conference, Pharmaceutical industry, Rhenium

AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will share three poster presentations at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California.

Key Points: 
  • AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will share three poster presentations at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California.
  • All presentations will be showcased during the Poster Reception on Thursday, August 10, 2023, beginning at 5:30 p.m. PT/8:30 p.m.
  • ET.
  • [TIPS-23] Safety and Feasibility Results from a Phase 1/2 Clinical Trial of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: The ReSPECT-GBM Trial
    [TIPS-22] A two-part, Phase 1 study of Rhenium (186Re) Obisbemeda (186RNL) delivered by convection enhanced delivery (CED) for recurrent, refractory, or progressive childhood ependymoma and high-grade glioma (HGG)

United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma

Retrieved on: 
Tuesday, July 25, 2023
Research, FDA, Genetics, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Partnership, University, UCSD, University of California, SOC, BTRC, USC, Doctor of Philosophy, San Diego, PFS, University of California, San Francisco, RVV, Literature, Patient, UCSF, HGG, Medicine, Vocimagene amiretrorepvec/flucytosine, Analysis of variance, Pharmaceutical industry, Medical imaging, MD

DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.

Key Points: 
  • DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.
  • The Phase 2 study of DB107 will investigate the impact of giving multiple doses of DB107 both directly at time of surgery and intravenously (IV).
  • The study also stratifies patients to more easily identify those individuals who benefit from treatment from those who do not.
  • “By fixing what is broken in clinical research we can conduct better studies and deliver the right treatments to the right patients.”

Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy™ for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Dimethyl sulfoxide, Survival, Cancer, Doctor of Philosophy, AAV, Organoid, SAN, HGG, CED, Annual general meeting, Siren, Neoplasm, Safety, Vaccine

Link here to review Siren’s ASGCT abstract and here to review the company’s launch press release also issued this morning.

Key Points: 
  • Link here to review Siren’s ASGCT abstract and here to review the company’s launch press release also issued this morning.
  • “We’re excited to present these potentially transformative data as we simultaneously introduce Universal AAV Immuno-Gene Therapy and Siren Biotechnology,” said Dr. Paulk.
  • “This novel approach represents a new, big, bold idea to fight cancer by combining the potential of AAV gene therapy and cytokine immunotherapy into a single modality.
  • Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer.

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, May 11, 2023
Pancreatic cancer, Injection, University, Gene, Quarter, Survival, Clinical trial, Quality of life, Lung cancer, University of Pennsylvania, NSCLC, SOC, Perelman School of Medicine at the University of Pennsylvania, Doctor of Philosophy, Associate, ASCO, Development, American Society of Clinical Oncology, Patient, Standard of care, Administration, HGG, Annual general meeting, Cell, American Society of Gene and Cell Therapy, Cancer, PD-1, Research, FDA, Therapy, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MPH, Valaciclovir, Society, MOS, Food, Prostate cancer, Pharmaceutical industry, Q3, Candel, Fellow of the Academy of Medical Sciences, MD

NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
  • Financial Results for the Quarter Ended March 31, 2023
    Research and Development Service Revenue, related party: Research and development service revenue, related party, was $0 for the first quarter of 2023 compared to $31,000 for the first quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $5.5 million for the first quarter of 2023 compared to $5.4 million for the first quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $4.2 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022.

Children's Hospital of Philadelphia Receives $10 Million Grant from the Gilbert Family Foundation to Accelerate Neurofibromatosis Research

Retrieved on: 
Tuesday, April 4, 2023
LGG, NF, Brain, Executive, Gene, CHOP, Prevalence, Genetics, Neuro-Oncology (journal), Elective surgery, Pediatrics, Neoplasm, Section, Heredity, HGAP, Hope, Neurofibromatosis, Research, Immunotherapy, VRI, Pain, CAR, Disorder, Neuro-ophthalmology, Genetic disorder, Standard of care, Patient, Investment, Neuro-oncology, HGG, Ophthalmology, Infant, Paratriathlon, NF1, Family, Neurology, BTI, Vision restoration therapy, Disease, Medical imaging, Pharmaceutical industry

PHILADELPHIA, April 4, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) today announced that it has received more than $10 million in a series of gifts to fund critical neurofibromatosis research from the Gilbert Family Foundation, a private foundation established by Dan and Jennifer Gilbert to accelerate a cure for neurofibromatosis type 1 (NF1). 

Key Points: 
  • The tumors that develop in the brain and body can lead to serious complications, including vision loss and severe pain.
  • The Gilbert Family Foundation was founded in 2015 to help accelerate a cure for NF1.
  • Nick Gilbert, the oldest son of Dan and Jennifer Gilbert, was diagnosed with NF1 as an infant and continues to battle the disease.
  • CHOP has received previous investments for its promising research as part of the Gilbert Family Foundation's Vision Restoration Initiative (VRI).

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 30, 2023
HSV, Pancreatic cancer, Insurance, Herpes simplex virus, University, Partnership, ICI, Survival, Clinical trial, Silicon Valley Bank, Immunotherapy, Nestin, Toxicity, Brain, NSCLC, Lung cancer, Doctor of Philosophy, TWELVE, Rated R, MS, University of Pennsylvania, Silicon, Development, HIV disease progression rates, Patient, Standard of care, Content discovery platform, Administration, HGG, Biology, PD-1, Research, Therapy, CADL, Tumor microenvironment, PD-L1, Valaciclovir, Nivolumab, Prostate cancer, Enlightenment, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Society, Candel, SOC, Cancer, Fellow of the Academy of Medical Sciences, MD

In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.

Key Points: 
  • In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.
  • Importantly, CAN-2409 demonstrated a favorable change in the trajectory of tumor growth in all patients for whom pre-enrollment scans were available.
  • The Company is encouraged by the results and plans to present additional data in Q3 2023.
  • Research and Development Expenses: Research and development expenses were $5.0 million for the fourth quarter of 2022 compared to $3.9 million for the fourth quarter of 2021, and $20.8 million for the full-year 2022 compared to $15.2 million for the full-year 2021.

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

Retrieved on: 
Monday, March 6, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Greehey Children's Cancer Research Institute, SOC, Kennedy Krieger Institute, MGMT, American Association for Cancer Research, Brain, Malignancy, Lung cancer, Neoplasm, USD, Temozolomide, Permeability, Machine learning, HGG, Computational biology, DNA, Pancreatic cancer, Central nervous system, Mouse, Therapy, DDR, Glioblastoma, Patient, Publication, Johns Hopkins, Multimedia, Society, GBM, Spironolactone, Breast cancer, TMZ, Methylation, Melanoma, UT Health San Antonio Cancer Center, CNS, FDA, Cancer, Traffic barrier, ODD, ML, ATRT, CDX, Starlight, Drug discovery, Metadata, Nursing, Pharmaceutical industry, Medical imaging, Lantern, Adult

Starlight will refer to the molecule LP-184, as it is developed in CNS indications, as “STAR-001”.

Key Points: 
  • Starlight will refer to the molecule LP-184, as it is developed in CNS indications, as “STAR-001”.
  • “Our portfolio of opportunities and pipeline in CNS cancers has grown five-fold and includes multiple indications lacking any accepted standard-of-care.
  • Starlight is planning several additional clinical programs for STAR-001 including adult and pediatric CNS cancers and combination regimens.
  • The clinical development of STAR-001 in CNS cancers beyond the Phase 1A trial will be conducted exclusively by Starlight.